Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240161 · ClinicalTrials.gov registry record
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
A clinical trial, sponsored by Marcelo F. Di Carli, MD, FACC.
- Completed
- Registry status
- 37
- Enrollment target
NCT01240161: Completed study, sponsored by Marcelo F. Di Carli, MD, FACC.
NCT01240161 is a clinical trial that has completed, run by Marcelo F. Di Carli, MD, FACC. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01240161 has completed, sponsored by Marcelo F. Di Carli, MD, FACC.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.
Interventions
- DRUG FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-12 |
| Est. Completion | 2016-03 |
What the finished NCT01240161 record still lists
NCT01240161 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT is the first listed.
NCT01240161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01240161 about?
NCT01240161 is a clinical study titled "Personalized Translational Platform for Biomarker Discovery in Brain Tumors". The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.
What is the current status of trial NCT01240161?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2009-12. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01240161?
The interventions under investigation include: FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT (DRUG).
Who is sponsoring clinical trial NCT01240161?
This trial is sponsored by Marcelo F. Di Carli, MD, FACC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia